The Sentinel Dual Filter Device Design Features & EU Clinical Trial Results
|
|
- Godfrey Charles
- 5 years ago
- Views:
Transcription
1 The Sentinel Dual Filter Device Design Features & EU Clinical Trial Results Nicolas M. Van Mieghem, MD, PhD, FESC Director of Interventional Cardiology Thoraxcenter, Erasmus MC Rotterdam
2 Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Grant/Research Support Consulting Fees/Honoraria Company Abbott Vascular, Medtronic, Boston Scientific; Claret Medical Claret Medical All TVT 2016 faculty disclosures are listed online and on the app.
3 Recent Trials and any 30 days % Patients with Strke at 30 Days 8% 7% 6% 5% 4% 3% 2% 4.0% 3.9% 5.5% 6.8% 7.0% 3.3% 4.1% 2.5% 4.9% 4.3% 1.5% 2.7% 5.5% 1% 0% CoreValve Extreme Risk N=489 Extreme Risk LOTUS RESPOND N=500 Portico CE Study N=103 LOTUS REPRISE II + Ext N=249 Direct Flow DISCOVER N=75 Extreme/High Risk 0.0% Evolut R CE Study N=60 Evolut R IDE N= 241* SAPIEN PARTNER IIB N=276 SAPIEN TVT HR N=12182 CoreValve High Risk N=390 High Risk SAPIEN XT PARTNER IIB N=284 SAPIEN 3 SAPIEN 3 PARTNER IIPARTNER II HR S3i N=583 N=1078 SAPIEN XT PARTNER IIA N=1011 Intermediate Risk * Disabling Stroke Meredith, et al., presented at PCR London Valves 2014; Adams, et al., N Engl J Med 2014; 370: ; Leon, et. al. presented at ACC 2013; Lefevre et al., J Am Coll Cardiol 2016; 1:; Popma, et al., J Am Coll Cardiol 2014; 63: ; Linke, et. al. presented at London Valves 2015; Van Mieghem, et al., presented at EuroPCR 2015; Kodali, et al., presented at ACC 2015; Holmes, et al., JAMA 2015; 313: ; Meredith, et al., presented at ACC 2015, 1 Williams, et. al. presented at ACC 2016; Thourani, et al, presented at ACC 2016
4 Next Gen TAVR & Major Stroke Meta-analysis of ~20 non-randomized, mostly FIM, valve-company sponsored studies 2.4% major stroke at 30-days Athappan, et al. A systematic review on the safety of second-generation transcatheter aortic valves. EuroIntervention 2016; 11:
5 Stroke Timing post TAVI Timing of Cerebrovascular Events (CVE) in FRANCE-2 Registry (n=3,191) CVE most frequently occur day 0-1 >50% are major strokes Median time to major stroke is 1 day D. Tchetche et al. JACC CV Int. 2014;7: Multi-center cohort of 1,061 TAVI patients CVE most frequently occur day 0-1 >50% are major strokes >95% of strokes are ischemic Nombela-Franco et al., Circulation 2012;126:
6
7
8 Sentinel EU Trials CLEAN TAVI SENTINEL - H MISTRAL - C
9 CLEAN TAVI A. Linke, MD, PhD - TCT 2014
10 CLEAN TAVI Endpoints A. Linke, MD, PhD - TCT 2014
11 MRI Findings Total Lesion Volume Lesion Number A. Linke, MD, PhD - TCT 2014
12 MISTRAL-C Design: multi-center double-blind randomized trial enrolling patients with symptomatic severe aortic stenosis and 1:1 randomization to TAVI with or without Sentinel EPD Aim: does Sentinel EPD affect new brain lesions & neurocognitive performance after TAVI Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
13 MISTRAL-C From January 2013 August patients were enrolled TAVI Procedure Day 0 TAVI 1 Day Randomization Sentinel vs. Control Transcranial Doppler Pathology TAVI + 5 Days Consent for TAVI & MISTRAL-C study 3T Neuro-MRi Neurocognitive testing 3T Neuro-MRi Neurocognitive testing Clinical neurological exam Clinical neurological exam Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
14 Brain MRI n=37 baseline MRI: 11% Median number of days to MRI: 5 (IQR 5-5) No FU MRI: 43% Perspective Other 14% Dead / Unstable 18% Reason for MRI dropout Delirium 11% Patient refused 21% Pacemaker 36% N=28 Dropout in other studies DEFLECT-I 24% DEFLECT-II 21% DEFLECT-III 41% PROTAVI-C 33% CLEAN 7% CLEAN 22% Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
15 Lesion Volume Overall 600 Lesion volume in mm P=0, Sentinel (n=22) No Sentinel (n=15) 600 Anterior 600 Posterior Lesion volume in mm Sentinel (n=22) P=0, No Sentinel (n=15) Lesion volume in mm Sentinel (n=22) P=0, No Sentinel (n=15) Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
16 Number o lesions Number of Lesions Overall P=0, Anterior 2 2 Sentinel (n=22) No Sentinel (n=15) Posterior Number of lesions (median) Sentinel (n=22) P=0,065 1 No Sentinel (n=15) Number of lesions (median) P=0, Sentinel (n=22) No Sentinel (n=15) Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
17 100% No new lesions Overall Proportion of patients (%) 50% 0% p=0,312 27% 13% Sentinel (n=22) No Sentinel (n=15) Anterior Posterior Proportion of patients (%) 100% 50% 0% p=0,065 50% 20% Sentinel (n=22) No Sentinel (n=15) Proportion of patients (%) 100% 50% 0% p=0,850 36% 33% Sentinel (n=22) No Sentinel (n=15) Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
18 Deterioration in neurocognitive status ITT 100% 90% Claret (n=28) No Claret (22) Proportion of patients (%) 80% 70% 60% 50% 40% 30% 20% 10% 0% p=0,017 p=0,248 p=0,105 p=0,272 27% 26% 25% 13% 8% 4% 5% 0% MMSE worsening MoCA worsening CES-D worsening NIHSS worsening Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
19 Histopathology of Retrieved Filters (n=31) Van Mieghem NM et al. EuroIntervention 2016 In Press July Issue
20 SENTINEL H Study Prevalence and etiopathology of thromboembolic debris during transcatheter interventional aortic valve replacement C.J. Jensen 1, A. Wolf 1, T. Schmitz 1, T. Schmidt 2, C. Frerker 2, T. Thielsen 2, U. Schäfer 3, N. Schofer 3, F. Deuschl 3, P. Frambach 4, D. Wagner 4, C. Kaiser 5, R. Jeger 5, E.J. Parker 6, M. Romero 7, E. Ladich 7, R. Virmani 7, C.K. Naber 1 1 Contilia heart and vascular center, department of cardiology and angiology, Elisabeth hospital, Essen, Germany; 2 AK St. Georg, Hamburg, Germany; 3 UKE Hamburg, Germany; 4 INCCI LUXEMBURG, Luxemburg; 5 Universitätsspital BASEL, Switzerland; 6 Haukeland clinic Bergen, Norway; 7 CV Path Institute, Inc., Gaithersburg, USA Jensen CJ et al. EuroPCR 2016
21 SENTINEL-H Prospective, multi-center, international all-comer study TAVI + Sentinel CPS Germany Luxemburg Suisse Norway Multiple TAVR designs SAPIEN S3 88 Sapien XT 8 Edwards Centera 1 BSC Lotus 37 Direct Flow 42 STJ Portico 10 Medtronic CV 9 Medtronic EvolutR 16 Symetis 1 Jena Valve 1 Histopathology by independent core lab CVPath (Gaithersburg, USA) Jensen CJ et al. EuroPCR 2016
22 Van Mieghem NM et al. Circulation 2013;176: Van Mieghem NM et al. JACC CV Int. 2015;8:718-24
23 Results N = 217 patients, mean age 83.7 years 98% transfemoral TAVI Procedural success (defined as both filters successfully deployed and retrieved) was 211/217 = 97% Remaining 6 patients all had the BCC Filter deployed In 98% of cases, there was no or insignificant interference with the TAVR device There were no cases of a dislocation of the Sentinel Device by the TAVI delivery catheter The median time to place Sentinel: 4 minutes Average contrast media to place Sentinel: 15±5 ml Jensen CJ et al. EuroPCR 2016
24 Debris Presence
25 Histopathology Proximal & Distal Filter
26 Debris per THV Design Overall BE SE ME BE (96) = Sapien 3 (88) + Sapien XT (8) SE (38) = EvolutR (16) + CoreValve Classic (9) + Portico (10) + Symetis (1) + Jenavalve (1) + Centera (1) ME (79) = Lotus (37) + Direct Flow (42) *The error bars represent 95% confidence intervals (+/ x SE)
27 In Conclusion Filter based cerebral protection with Sentinel during TAVR will capture debris en route to the brain in virtually all patients Debris etiology is diverse (thrombus and tissue) Small randomized trials hint towards reductions in new brain lesions by MRI neurocognitive preservation less brain insults SENTINEL US IDE Trial results are eagerly awaited
The Case for and Against Cerebral Embolic Protection During TAVR. Susheel Kodali, MD
The Case for and Against Cerebral Embolic Protection During TAVR Susheel Kodali, MD Director, Structural Heart & Valve Center Columbia University Medical Center New York Presbyterian Hospital Disclosure
More informationTAVI limitations for low risk patients
TAVI limitations for low risk patients Dr. T. Modine / P. Lancellotti MD, PhD, MBA CHRU de Lille, France Potential conflicts of interest Speaker's name: Thomas Modine I have the following potential conflicts
More informationStrokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationRole of Embolic Protection during TAVR
Role of Embolic Protection during TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Disclosure Co PI for Sentinel Trial
More informationTAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationStrokes After TAVR. Incidence (past and present) Multi-factorial Origin
Strokes After TAVR Incidence (past and present) Multi-factorial Origin Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic All faculty disclosures are
More informationComplicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato
Complicanze durante TAVI Brambilla Nedy IRCCS Policlinico San Donato 0 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93 106 113 121 151 171 186 201 225 267 283 294 311 349 502 515 709 1007 Number of
More informationUpdate on TAVR. Howard C. Herrmann, MD, FACC, MSCAI
Update on TAVR Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director, Cardiac Cath Labs, Hospital
More informationIs Cerebral Embolic Protection Needed for TAVR?
Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials Samir Kapadia, MD Professor of Medicine Section head, Interventional
More informationSentinel Dual Filter Device: Technology Overview and Status of the CLEAN-TAVI Randomized Trial. Martin B. Leon, MD
8 mins Sentinel Dual Filter Device: Technology Overview and Status of the CLEAN-TAVI Randomized Trial Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationCerebral Protection In Transcatheter Aortic Valve Replacement The SENTINEL Study. Susheel Kodali, MD Columbia University Medical Center
Cerebral Protection In Transcatheter Aortic Valve Replacement The SENTINEL Study Susheel Kodali, MD Columbia University Medical Center Disclosure Statement of Financial Interest Susheel Kodali, MD Within
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More informationCoreValve High Risk Study - Neu
CoreValve High Risk Study - Neu Adams DH et al. NEJM 2014 CoreValve US Pivotal Trial Reardon MJ et al. ACC 2015 Stroke incidence and mortality after TAVI Meta-analysis of 10,037 published patients Stroke
More informationEmbolic Protection Devices for Transcatheter Aortic Valve Replacement
Embolic Protection Devices for Transcatheter Aortic Valve Replacement James M. McCabe, MD Medical Director, Cardiac Cath Lab University of Washington Seattle, WA Disclosures Proctoring and honoraria for
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationProtection Devices for Stroke Prevention Do the Data support their Routine Use?
ACC 2015 San Diego, March 14-16 nd, 2015 Protection Devices for Stroke Prevention Do the Data support their Routine Use? Eberhard Grube MD, FACC University Hospital, Dept of Medicine II, Bonn, Germany
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationCurrent Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationThe SAPIEN 3 TAVI Advantage
Edwards SAPIEN 3 Valve The SAPIEN 3 TAVI Advantage... The SAPIEN 3 TAVI Advantage The clear choice for your patients and your TAVI program Advanced valve and system designed to simplify procedures Consistent
More informationHow to Prevent Thromboembolic Complications in TAVI
How to Prevent Thromboembolic Complications in TAVI PETER WENAWESER, MD Swiss Cardiovascular Centre, University Hospital, Bern, Switzerland Potential Conflicts of Interest Proctoring and lecture fees from
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationThe Sentinel US Pivotal Clinical Trial Design
The Sentinel US Pivotal Clinical Trial Design Susheel Kodali, MD Director, Structural Heart & Valve Center Columbia University Medical Center New York Presbyterian Hospital Disclosure Statement of Financial
More informationWhy Cerebral Protection after TAVR Will Become the Standard of Care
Vancouver, June 5 th, 2014 Why Cerebral Protection after TAVR Will Become the Standard of Care Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Stanford University,
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationBuilding the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data
Building the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data Jeffrey W. Moses, MD Professor of Medicine Director, Interventional Cardiac Therapeutics Columbia University Medical
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationNeuroprotection During TAVR
Neuroprotection During TAVR Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac Catheterization Laboratories Cleveland Clinic Cleveland Clinic Disclosure Co
More informationTrans Aortic Valve Replacement Update: 2016 & Beyond
Trans Aortic Valve Replacement Update: 2016 & Beyond Rajiv Jauhar, MD, FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital, Manhasset 1 DISCLOSURE POLICY Northwell
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationtranscatheter heart valve: THV TAVI transcatheter aortic valve implantation
transcatheter heart valve: THV TAVI transcatheter aortic valve implantation Hideki OSHIMA 1. はじめに transcatheter heart valve: THV 1) transcatheter aortic valve implantation: TAVI transcatheter mitral valve
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationA Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class?
TVT Chicago Thursday 16th of June 2016 Session 1: TAVR 2016 Highlights and Controversies A Thoughtful Synthesis of the TAVR Landscape: What s New, What s Needed and is There a Best-in-Class? Ian T. Meredith
More informationThe Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy
The Future of Medicine Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy FIRST PATIENT TO UNDERGO PTCA FIRST PATIENT TO UNDERGO TAVI Grüntzig
More informationVinod H. Thourani, MD, FACC, FACS
Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationStrokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future)
Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future) Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informatione Corrado Tamburino, MD, PhD
Transcatheter Aortic Valve Implantation Stroke: etiology ogy and prevention e Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular
More informationLotus Valve System for Transcatheter Aortic Valve Implantation/Replacement (TAVI/R) Evidence
X Congreso Coilegio Colombiano Santiago de Cali, 29-31 Octubre des 2014 Lotus Valve System for Transcatheter Aortic Valve Implantation/Replacement (TAVI/R) Evidence Eberhard Grube MD, FACC, FSCAI University
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationTAVR: Current Valve Types. Patient Selection
TAVR: Current Valve Types. Patient Selection Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital
More informationPost-TAVI Cerebral Embolisms and Potential Protection Means
Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest
More informationL evoluzione nel management della valvulopatia aortica
L evoluzione nel management della valvulopatia aortica Giuseppe Tarantini, MD, PhD, FESC Director of Interventional Cardiology University of Padua GISE president TAVI: BIG BANG 2002 TAVI - EVOLUTIONs Commitment
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationAccepted Manuscript. Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data?
Accepted Manuscript Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data? Azeem Latib, MD, Matteo Pagnesi, MD PII: S0735-1097(16)36808-5 DOI: 10.1016/j.jacc.2016.10.036
More informationCurrent Controversies. Subclinical and clinical valve thrombosis
Chapter 19: Current controversies, ongoing trials, new valves, and future directions Sukhdeep S. Basra, MD, MPH, Michael J. Mack, MD The Heart Hospital Baylor Plano, Texas Transcatheter Aortic Valve Replacement
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationState of the Art and Future perspective
State of the Art and Future perspective Giuseppe Tarantini, MD, PhD, FESC Associate professor University of Padua Director Interventional Cardiology Dpt of Cardiac Thoracic and Vascular Sciences, Padua
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationTAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationThe Lotus Valve, The Latest Developments and Future Aspects. Professor Jan Harnek MD PhD FESC Lund University Sweden
The Lotus Valve, The Latest Developments and Future Aspects Professor Jan Harnek MD PhD FESC Lund University Sweden Potential Conflicts of Interest Speaker s name: Jan Harnek MD PhD jan.harnek@gmail.com
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationAortic Valve Controversies Beyond risk assessment: TAVI for Everybody
Aortic Valve Controversies Beyond risk assessment: TAVI for Everybody Anna Sonia Petronio, MD, FESC Head of Cardiac Catheteriza8on Lab Cardiothoracic and Vascular Department University of Pisa, Italy 1.
More informationSubclinical Thrombosis of Bioprosthetic Aortic Valves: Is It Clinically Relevant? Tarun Chakravarty, MD
Subclinical Thrombosis of Bioprosthetic Aortic Valves: Is It Clinically Relevant? Tarun Chakravarty, MD Interventional Cardiology Cedars-Sinai Heart Institute Disclosures Consultant and proctor for Edwards
More informationFederico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC
TAVR: When Things go Wrong Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC Disclosures Academic Echo Core Lab Abbott / St Jude Medical Edwards Medtronic
More informationTAVR for Complex Aortic Valvular Conditions
TAVR for Complex Aortic Valvular Conditions Wilson Y. Szeto, MD Professor of Surgery Chief, Cardiovascular Surgery at Penn Presbyterian Surgical Director, Transcatheter Cardio-Aortic Therapies Associate
More informationEberhard Grube MD, FACC, FSCAI
TAVI - Summit 2012 Seoul, September 8, 2012 Next Generation TAVI Systems Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São Paulo,
More informationSevere Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative
Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Samin K. Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationStrokes After TAVR: Perspectives from the US CoreValve Trials
Strokes After TAVR: Perspectives from the US CoreValve Trials Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Clinical Services Beth Israel Deaconess
More information3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong
3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationProgress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
More informationTranscatheter heart valve thrombosis
Transcatheter heart valve thrombosis Jeroen J Bax Dept Cardiology Leiden, The Netherlands New York, 2017 The department of Cardiology of the Leiden University Medical center received research grants from
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationMild paravalvular regurgitation is not an independent predictor of mortality following TAVI
Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationDO WE NEED TO DO BETTER?
A critical review of the neurological effects of invasive cardiac procedures: DO WE NEED TO DO BETTER? Pieter Stella, MD, PhD University Medical Center Utrecht, The Netherlands Disclosure - Member Advisory
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationParavalvular Regurgitation is a Risk Factor Following TAVI
Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationTAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion
TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion Moderator: Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationTAVI Technology and Procedural Changes
TCT AP 2013 Seoul, South Korea April, 2013 TAVI Technology and Procedural Changes Eberhard Grube MD, FACC, FSCAI University Hospital, Dept of Medicine II, Bonn, Germany Hospital Alemão Oswaldo Cruz, São
More informationResults of Transfemoral Transcatheter Aortic Valve Implantation
Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationANTICOAGULATION IN SPECIFIC POPULATIONS: BIOLOGICAL HEART VALVES, TAVI
ESC Cardiovascular Round Table 27 March 2017, Amsterdam ANTICOAGULATION IN SPECIFIC POPULATIONS: BIOLOGICAL HEART VALVES, TAVI Stephan Windecker Department of Cardiology Swiss Cardiovascular Center Bern
More informationEmerging Transcatheter Aortic Valve Technologies
East Meets West: Emerging Transcatheter Aortic Valve Technologies Emerging valve systems and iterative technologies from around the world and how they could shape global practice going forward. BY FEDERICO
More informationExtension to medium and low risk patients? Friedrich Eckstein University Hospital Basel
TAVI CON Extension to medium and low risk patients? Friedrich Eckstein University Hospital Basel Extension to medium and low risk patients? In octogenerians already reality in most of the swiss clinics!?
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationCerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)
Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR) Michael Mack, MD, Michael Acker, MD, Steve Messe, MD For the Cardiothoracic Surgical Trials Network (CTSN) American
More informationTAVR or SAVR A glimpse into the future
TAVR or SAVR A glimpse into the future Örjan Friberg Örebro University Hospital Sweden Prediction is very difficult, especially if it s about the future. Niels Bohr None Conflicts of interest If In the
More informationThe TAVI Journey: Update on Evidence And Future trials
The TAVI Journey: Update on Evidence And Future trials Philippe Généreux, MD Interventional Cardiologist, Hôpital du Sacré-Coeur de Montréal, Canada Director, Angiographic Core Laboratory, Cardiovascular
More informationFor the SURTAVI Investigators
Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter
More informationTranscatheter aortic valve replacement in intermediate and low risk patients-clinical evidence
Perspective Transcatheter aortic valve replacement in intermediate and low risk patients-clinical evidence Sameer Arora, John P. Vavalle Division of Cardiology, University of North Carolina School of Medicine,
More informationOutcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and
Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American
More informationPredictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke
Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke From the CENTER-Collaboration Wieneke Vlastra, MD Heart Center, Amsterdam UMC, University
More information